Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP7214
- Development stage
- Phase 2
- Lead developer
- Rhizen Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RP7214 is an orally bioavailable small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme essential for de novo pyrimidine synthesis. By inhibiting DHODH, RP7214 disrupts nucleotide biosynthesis required for the proliferation of rapidly dividing cells and viral replication. This mechanism confers potential antineoplastic, anti-inflammatory, and antiviral activities. Preclinical studies have demonstrated its efficacy in models of acute myeloid leukemia (AML) and SARS-CoV-2 infection. In clinical trials, it has shown favorable safety and pharmacokinetic profiles in healthy volunteers. The drug is being developed primarily for indications including AML, chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and COVID-19 infections[1][2][3][4][6][7].
- Other names
- DHODH inhibitor RP7214
02
Targets
DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)
Beyond the preview
Go deeper on RP7214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP7214.